S&P 500   2,685.40 (+0.82%)
DOW   22,913.02 (+1.03%)
QQQ   197.59 (+0.56%)
AAPL   260.55 (-0.73%)
FB   168.38 (+1.71%)
MSFT   165.00 (-0.52%)
GOOGL   1,192.09 (+0.75%)
AMZN   2,012.86 (+0.76%)
CGC   14.50 (+1.12%)
NVDA   260.53 (-2.93%)
BABA   198.00 (+0.79%)
MU   46.64 (+0.58%)
GE   7.10 (-2.47%)
TSLA   544.97 (+5.57%)
AMD   47.88 (+0.76%)
T   30.37 (+3.16%)
ACB   0.80 (+0.00%)
F   4.73 (+4.42%)
NFLX   373.64 (-1.66%)
GILD   74.77 (-3.82%)
DIS   101.10 (+1.53%)
S&P 500   2,685.40 (+0.82%)
DOW   22,913.02 (+1.03%)
QQQ   197.59 (+0.56%)
AAPL   260.55 (-0.73%)
FB   168.38 (+1.71%)
MSFT   165.00 (-0.52%)
GOOGL   1,192.09 (+0.75%)
AMZN   2,012.86 (+0.76%)
CGC   14.50 (+1.12%)
NVDA   260.53 (-2.93%)
BABA   198.00 (+0.79%)
MU   46.64 (+0.58%)
GE   7.10 (-2.47%)
TSLA   544.97 (+5.57%)
AMD   47.88 (+0.76%)
T   30.37 (+3.16%)
ACB   0.80 (+0.00%)
F   4.73 (+4.42%)
NFLX   373.64 (-1.66%)
GILD   74.77 (-3.82%)
DIS   101.10 (+1.53%)
S&P 500   2,685.40 (+0.82%)
DOW   22,913.02 (+1.03%)
QQQ   197.59 (+0.56%)
AAPL   260.55 (-0.73%)
FB   168.38 (+1.71%)
MSFT   165.00 (-0.52%)
GOOGL   1,192.09 (+0.75%)
AMZN   2,012.86 (+0.76%)
CGC   14.50 (+1.12%)
NVDA   260.53 (-2.93%)
BABA   198.00 (+0.79%)
MU   46.64 (+0.58%)
GE   7.10 (-2.47%)
TSLA   544.97 (+5.57%)
AMD   47.88 (+0.76%)
T   30.37 (+3.16%)
ACB   0.80 (+0.00%)
F   4.73 (+4.42%)
NFLX   373.64 (-1.66%)
GILD   74.77 (-3.82%)
DIS   101.10 (+1.53%)
S&P 500   2,685.40 (+0.82%)
DOW   22,913.02 (+1.03%)
QQQ   197.59 (+0.56%)
AAPL   260.55 (-0.73%)
FB   168.38 (+1.71%)
MSFT   165.00 (-0.52%)
GOOGL   1,192.09 (+0.75%)
AMZN   2,012.86 (+0.76%)
CGC   14.50 (+1.12%)
NVDA   260.53 (-2.93%)
BABA   198.00 (+0.79%)
MU   46.64 (+0.58%)
GE   7.10 (-2.47%)
TSLA   544.97 (+5.57%)
AMD   47.88 (+0.76%)
T   30.37 (+3.16%)
ACB   0.80 (+0.00%)
F   4.73 (+4.42%)
NFLX   373.64 (-1.66%)
GILD   74.77 (-3.82%)
DIS   101.10 (+1.53%)
Log in

NASDAQ:OXFDOxford Immunotec Global Stock Price, Forecast & News

$9.78
+0.11 (+1.14 %)
(As of 04/7/2020 03:07 PM ET)
Add
Compare
Today's Range
$9.78
Now: $9.78
$10.25
50-Day Range
$9.15
MA: $11.96
$14.98
52-Week Range
$8.37
Now: $9.78
$17.77
Volume18,852 shs
Average Volume315,236 shs
Market Capitalization$256.24 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. The company develops and markets T-SPOT.TB test used to test for tuberculosis. It is also developing C6 Borrelia burgdorferi (Lyme) ELISA kit, which measures Lyme specific antibodies; and T-SPOT.CMV test that utilizes its T-SPOT technology platform to measure the strength of a patient's cellular immune response to antigens specific to cytomegalovirus (CMV), as well as provides information for informing management strategies of patients at risk of CMV infection and disease, such as transplant patients. The company markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors internationally. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Read More
Oxford Immunotec Global logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$73.71 million
Cash Flow$0.02 per share
Book Value$8.08 per share

Profitability

Net Income$-1,810,000.00

Miscellaneous

Employees215
Market Cap$256.24 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.


Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

How has Oxford Immunotec Global's stock been impacted by COVID-19 (Coronavirus)?

Oxford Immunotec Global's stock was trading at $12.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OXFD shares have decreased by 19.8% and is now trading at $9.78. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Oxford Immunotec Global?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Oxford Immunotec Global.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Oxford Immunotec Global.

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its earnings results on Monday, March, 2nd. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.04. The company earned $18.11 million during the quarter, compared to the consensus estimate of $17.29 million. Oxford Immunotec Global had a negative return on equity of 0.62% and a negative net margin of 2.45%. View Oxford Immunotec Global's earnings history.

What guidance has Oxford Immunotec Global issued on next quarter's earnings?

Oxford Immunotec Global issued an update on its first quarter 2020 IntraDay earnings guidance on Friday, April, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.1-14.1 million, compared to the consensus revenue estimate of $12.89 million.

What price target have analysts set for OXFD?

2 Wall Street analysts have issued 12 month price objectives for Oxford Immunotec Global's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Oxford Immunotec Global's share price to reach $20.00 in the next year. This suggests a possible upside of 104.5% from the stock's current price. View analysts' price targets for Oxford Immunotec Global.

Has Oxford Immunotec Global been receiving favorable news coverage?

News headlines about OXFD stock have trended very negative recently, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oxford Immunotec Global earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutOxford Immunotec Global.

Are investors shorting Oxford Immunotec Global?

Oxford Immunotec Global saw a increase in short interest in March. As of March 13th, there was short interest totaling 422,500 shares, an increase of 10.7% from the February 27th total of 381,800 shares. Based on an average daily volume of 126,900 shares, the short-interest ratio is presently 3.3 days. Approximately 1.8% of the shares of the company are short sold. View Oxford Immunotec Global's Current Options Chain.

Who are some of Oxford Immunotec Global's key competitors?

What other stocks do shareholders of Oxford Immunotec Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Immunomedics (IMMU), AbbVie (ABBV), Intel (INTC), Gold Resource (GORO), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Gilead Sciences (GILD), Halozyme Therapeutics (HALO), Sangamo Therapeutics (SGMO) and Advanced Micro Devices (AMD).

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the following people:
  • Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)
  • Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)
  • Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 42)
  • Mr. Stefan C. Linn, Chief Operating Officer (Age 54)
  • Ms. Karen C. Koski, VP of Strategy & Investor Relations

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $9.78.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $256.24 million and generates $73.71 million in revenue each year. The company earns $-1,810,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe. View additional information about Oxford Immunotec Global.

What is Oxford Immunotec Global's official website?

The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: What is a support level?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel